[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613337":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":10,"centralContacts":36,"locations":42,"responsibleParty":59,"collaborators":10,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":10,"enrollmentInfo":71,"targetDuration":10,"studyType":74,"phases":10,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"City of Hope Medical Center","OTHER",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"HCC (Discovery, Small RNA-seq)",null,"Patient diagnosed with hepatocellular carcinoma, including cases with HBV-, HCV-, and NBNC-related etiologies. Blood or other biospecimens will be collected for multi-omics profiling",[13,14],"Diagnostic Test: Small RNA sequence","Diagnostic Test: Rt-qPCR",{"label":16,"type":10,"description":17,"interventionNames":18},"Chronic Liver Disease (CLD) cohort","Patients with chronic liver disease, including liver cirrhosis and chronic hepatitis, without evidence of hepatocellular carcinoma.\n\nBlood or other biospecimens will be collected for multi-omics profiling.",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Healthy Controls","Healthy individuals without known liver disease or malignancy who will provide blood or other biospecimens as normal controls for biomarker evaluation.",[13,14],[24,29,33],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"DIAGNOSTIC_TEST","Small RNA sequence","Comprehensive small RNA sequencing of serum or plasma-derived cf-tsRNAs to identify candidate biomarkers distinguishing HCC from NDC.",[16,9,20],{"type":25,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"Rt-qPCR","Construction of integrated cf- tsmiRNAs diagnostic classifier using machine learning",[16,9,20],{"type":25,"name":30,"description":34,"armGroupLabels":35,"otherNames":10},"PCR-based validation of the tsRNA panel",[16,9,20],[37],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},"Goel Ajay, PhD","CONTACT","626-218-3452","ajgoel@coh.org",[43],{"facility":5,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Duarte","California","91016","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-117.97729,34.13945,{"lat":54,"lon":53},[57],{"name":58,"role":39,"phone":40,"phoneExt":10,"email":41},"Ajay Goel, PhD",{"type":60,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100613337","project-for-multi-omics-based-early-detection-of-hepatocellular-carcinoma-promethea-study-100613337",false,"NCT07265271","Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)","CENTINEL","Inclusion Criteria:\n\n* Adults aged 18 to 100 years.\n* A histologically confirmed diagnosis of hepatocellular carcinoma.\n* A clinically diagnosed as chronic liver disease, including chronic hepatitis or liver cirrhosis, without evidence of hepatocellular carcinoma.\n* Healthy volunteers without known liver disease or malignancy.\n* Received standard diagnostic and staging procedures as per local guidelines\n* Availability of blood or other biospecimens.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Lack of or inability to provide informed consent\n* History of other active malignancies within the past 5 years\n* Previous liver transplantation\n* Severe systemic infection or inflammatory disease at the time of enrollment\n* Inadequate sample quality or quantity",true,"ALL","18 Years",{"count":72,"type":73},600,"ESTIMATED","OBSERVATIONAL","Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited.\n\nThis study seeks to develop a multi-omics-based liquid biopsy assay, especially focusing on ncRNAs (e.g. tsRNA, miRNA, circRNA, lncRNA, etc.) for accurate detection of early-stage HCC.",[77],"Hepatocellular Carcinoma (HCC)",[79,80,81,82,83],"HCC","Liver cancer","tsRNA","Liquid Biopsy","Early Detection","2026-06-30",{"date":86,"type":87},"2026-07-01","ACTUAL",{"date":89,"type":87},"2025-01-15",{"date":91,"type":73},"2028-06-18",{"name":5,"class":6},1]